Study of alzheimer's disease risk genes using blood-brain barrier assembloids

Active Grant Awarded

Award ID
R21AG100393
Recipient
Awarding agency
Obligated
$462,593

Award facts

Assistance listing
93.866 Aging Research
Completion date 10% complete
Place of performance
Cincinnati, OH 45229, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through its National Institute on Aging, awarded Childrens Hospital Medical Center $462,593 on September 9, 2026, under Grant R21AG100393 in the Aging Research program (CFDA 93.866). The grant funds development of a novel three-dimensional human blood-brain barrier assembloid platform, derived from human induced pluripotent stem cells and engineered with isogenic knock-ins of Alzheimer's disease risk variants, including APOE, TREM2, ACE, and CLU. The work aims to uncover variant-specific contributions to blood-brain barrier dysfunction and to identify associated gene regulatory pathways and neurovascular interaction mechanisms driving barrier decline in Alzheimer's disease. The application's preliminary data show that assembloids derived from iPSCs of patients carrying APOE4/4 alleles exhibit tight junction disruption and glucose transporter deficiency, and that CRISPR-Cas9 knock-in of APOE4 into healthy control iPSCs recapitulates these deficits. The period of performance runs from the award date through August 31, 2028, with performance located in Cincinnati, Ohio 45229. The program's purpose is to support biomedical, social, and behavioral research and training on the aging process and its diseases, with particular emphasis on preventing and treating Alzheimer's disease and related dementias. The assistance type is grant.

Description

Abstract
The blood-brain barrier (BBB) plays an essential role in maintaining central nervous system homeostasis by regulating molecular transport and immune surveillance. Emerging evidence indicates that BBB breakdown is an early event in alzheimer's disease (ad) pathogenesis and may precede cognitive decline. Genetic risk factors for ad-such as variants in apoe, TREM2, ACE, and CLU-have been implicated in vascular dysfunction, yet the mechanistic basis by which these variants contribute to BBB breakdown remains poorly defined. A key limitation in addressing this knowledge GAP is the absence of physiologically relevant human BBB models that incorporate both ad-associated genetic risk and neurovascular complexity. To overcome this challenge, we propose to develop a novel 3D human BBB assembloid platform derived from human induced pluripotent stem cells (IPSC), engineered with isogenic knock-INS of ad risk variants. Our preliminary data demonstrate that BBB assembloids derived from ipscs of ad patients carrying APOE4/4 alleles exhibit hallmark features of BBB dysfunction, including tight junction disruption and glucose transporter deficiency-mirroring clinical findings in ad. Furthermore, crispr-CAS9-mediated knock-in of APOE4 into healthy control ipscs recapitulates these deficits, directly linking this variant to BBB pathology. Single-cell transcriptomic profiling of these assembloids reveals enrichment of ad risk gene expression in BBB-resident cell types and identifies impaired neurovascular crosstalk, characterized by diminished extracellular matrix ligand- receptor interactions and weakened WNT signaling pathways. We hypothesize that engineering isogenic ad risk variants into human BBB assembloids will uncover the variant-specific contributions to BBB dysfunction and identify associated gene regulatory pathways and neurovascular interaction mechanisms driving BBB decline in ad. We propose two specific aims: aim 1 will define the causal contributions of apoe, TREM2, ACE, and CLU risk variants to structural and functional breakdown of the BBB. Aim 2 integrates single-cell transcriptomics and spatial sequencing to map dysregulated gene regulatory networks and disrupted ligand-receptor signaling across spatially resolved neurovascular cell pairs affected by ad risk variants. This project will establish a high-fidelity human BBB platform for mechanistic interrogation of ad genetic risk, directly advancing NIH priorities in ad and vascular contributions to dementia. By integrating stem cell- derived assembloids, crispr editing, and multi-omics approaches, this work will provide foundational insights into ad-related BBB pathology, paving the way for future therapeutic strategies targeting the neurovascular interface. Deliverables will include open-access omics datasets, validated isogenic IPSC lines, and analytical pipelines to advance the field's understanding of vascular contributions to ad.

Quick answers

Who received award R21AG100393?

R21AG100393 was awarded to Childrens Hospital Medical Center by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R21AG100393 worth?

$462,593 has been obligated on R21AG100393.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award